Evidence map›Paper›PMID 25074541›Full record

ArticleNeuro-oncology2015

Nitroxoline induces apoptosis and slows glioma growth in vivo.

Jelena Lazovic, Lea Guo, Jonathan Nakashima, Leili Mirsadraei, William Yong, Hyun J Kim, Benjamin Ellingson, Hong Wu, Whitney B Pope

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 56 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Induction of Programmed Cell Death inAntioxidants (Basel, Switzerland) · 2023
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Jelena LazovicDepartment of Radiological Sciences, Ronald Reagan UCLA Medical Center, Los Angeles, California (J.L., L.G., H.J.K., B.E., W.B.P.); Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California (J.N., H.W.); Department of Pathology, University of California San Diego Medical Center, San Diego, California (L.M.); Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California (W.Y.); Department of Biostatistics, Fielding School of Public Health and Department of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California (H.J.K.).
Lea GuoDepartment of Radiological Sciences, Ronald Reagan UCLA Medical Center, Los Angeles, California (J.L., L.G., H.J.K., B.E., W.B.P.); Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California (J.N., H.W.); Department of Pathology, University of California San Diego Medical Center, San Diego, California (L.M.); Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California (W.Y.); Department of Biostatistics, Fielding School of Public Health and Department of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California (H.J.K.).
Jonathan NakashimaDepartment of Radiological Sciences, Ronald Reagan UCLA Medical Center, Los Angeles, California (J.L., L.G., H.J.K., B.E., W.B.P.); Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California (J.N., H.W.); Department of Pathology, University of California San Diego Medical Center, San Diego, California (L.M.); Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California (W.Y.); Department of Biostatistics, Fielding School of Public Health and Department of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California (H.J.K.).
Leili MirsadraeiDepartment of Radiological Sciences, Ronald Reagan UCLA Medical Center, Los Angeles, California (J.L., L.G., H.J.K., B.E., W.B.P.); Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California (J.N., H.W.); Department of Pathology, University of California San Diego Medical Center, San Diego, California (L.M.); Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California (W.Y.); Department of Biostatistics, Fielding School of Public Health and Department of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California (H.J.K.).
William YongDepartment of Radiological Sciences, Ronald Reagan UCLA Medical Center, Los Angeles, California (J.L., L.G., H.J.K., B.E., W.B.P.); Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California (J.N., H.W.); Department of Pathology, University of California San Diego Medical Center, San Diego, California (L.M.); Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California (W.Y.); Department of Biostatistics, Fielding School of Public Health and Department of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California (H.J.K.).
Hyun J KimDepartment of Radiological Sciences, Ronald Reagan UCLA Medical Center, Los Angeles, California (J.L., L.G., H.J.K., B.E., W.B.P.); Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California (J.N., H.W.); Department of Pathology, University of California San Diego Medical Center, San Diego, California (L.M.); Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California (W.Y.); Department of Biostatistics, Fielding School of Public Health and Department of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California (H.J.K.).
Benjamin EllingsonDepartment of Radiological Sciences, Ronald Reagan UCLA Medical Center, Los Angeles, California (J.L., L.G., H.J.K., B.E., W.B.P.); Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California (J.N., H.W.); Department of Pathology, University of California San Diego Medical Center, San Diego, California (L.M.); Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California (W.Y.); Department of Biostatistics, Fielding School of Public Health and Department of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California (H.J.K.).
Hong WuDepartment of Radiological Sciences, Ronald Reagan UCLA Medical Center, Los Angeles, California (J.L., L.G., H.J.K., B.E., W.B.P.); Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California (J.N., H.W.); Department of Pathology, University of California San Diego Medical Center, San Diego, California (L.M.); Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California (W.Y.); Department of Biostatistics, Fielding School of Public Health and Department of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California (H.J.K.).
Whitney B PopeDepartment of Radiological Sciences, Ronald Reagan UCLA Medical Center, Los Angeles, California (J.L., L.G., H.J.K., B.E., W.B.P.); Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California (J.N., H.W.); Department of Pathology, University of California San Diego Medical Center, San Diego, California (L.M.); Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California (W.Y.); Department of Biostatistics, Fielding School of Public Health and Department of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California (H.J.K.).
University of California San Diego Medical Center · USRonald Reagan UCLA Medical Center · USUniversity of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNitroxoline is an FDA-approved antibiotic with potential antitumor activity. Here we evaluated whether nitroxoline has antiproliferative properties on glioma cell growth in vitro and in vivo using glioma cell lines and a genetically engineered PTEN/KRAS mouse glioma model.

methodsThe effect of nitroxoline treatment on U87 and/or U251 glioma cell proliferation, cell-cycle arrest, invasion, and ability to induce an apoptotic cascade was determined in vitro. Magnetic resonance imaging was used to measure glioma volumes in genetically engineered PTEN/KRAS mice prior to and after nitroxoline therapy. Induction of apoptosis by nitroxoline was evaluated at the end of treatment using terminal deoxyribonucleotidyl transferase (TDT)-mediated dUTP-digoxigenin nick end labeling (TUNEL).

resultsNitroxoline inhibited the proliferation and invasion of glioblastoma cells in a time- and dose-dependent manner in vitro. Growth inhibition was associated with cell-cycle arrest in G1/G0 phase and induction of apoptosis via caspase 3 and cleaved poly(ADP-ribose) polymerase. In vivo, nitroxoline-treated mice had no increase in tumor volume after 14 days of treatment, whereas tumor volumes doubled in control mice. Histological examination revealed 15%-20% TUNEL-positive cells in nitroxoline-treated mice, compared with ∼5% in the control group.

conclusionNitroxoline induces apoptosis and inhibits glioma growth in vivo and in vitro. As an already FDA-approved treatment for urinary tract infections with a known safety profile, nitroxoline could move quickly into clinical trials pending confirmatory studies.

Indexed as

AnimalsAnti-Infective Agents, UrinaryAntineoplastic AgentsApoptosisBrain NeoplasmsCell Cycle CheckpointsCell Line, TumorCell ProliferationDisease Models, AnimalGlioblastomaMiceNitroquinolinesAnti-Infective Agents, UrinaryAntineoplastic AgentsNitroquinolinesnitroxoline8-hydroxy-5-nitroquinolineglioma animal modelinvasionnitroxolinePTEN

Identifiers

PMID25074541
PMCPMC4483047
OpenAlexW1966245361

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.